AR092993A1 - Laquinimod para reducir el daño talamico en la esclerosis multiple - Google Patents
Laquinimod para reducir el daño talamico en la esclerosis multipleInfo
- Publication number
- AR092993A1 AR092993A1 ARP130103705A ARP130103705A AR092993A1 AR 092993 A1 AR092993 A1 AR 092993A1 AR P130103705 A ARP130103705 A AR P130103705A AR P130103705 A ARP130103705 A AR P130103705A AR 092993 A1 AR092993 A1 AR 092993A1
- Authority
- AR
- Argentina
- Prior art keywords
- laquinimod
- subject
- multiple sclerosis
- damage
- affected
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 9
- 229960004577 laquinimod Drugs 0.000 title abstract 9
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 4
- 230000000542 thalamic effect Effects 0.000 abstract 6
- 206010071068 Clinically isolated syndrome Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 2
- 206010044565 Tremor Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 208000018198 spasticity Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713256P | 2012-10-12 | 2012-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092993A1 true AR092993A1 (es) | 2015-05-13 |
Family
ID=50475887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103705A AR092993A1 (es) | 2012-10-12 | 2013-10-11 | Laquinimod para reducir el daño talamico en la esclerosis multiple |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140107154A1 (https=) |
| EP (1) | EP2961406A4 (https=) |
| JP (1) | JP2015533163A (https=) |
| KR (1) | KR20150080509A (https=) |
| CN (1) | CN105263325A (https=) |
| AR (1) | AR092993A1 (https=) |
| AU (2) | AU2013329348A1 (https=) |
| BR (1) | BR112015007782A2 (https=) |
| CA (1) | CA2884272A1 (https=) |
| CL (2) | CL2015000732A1 (https=) |
| EA (1) | EA201590726A1 (https=) |
| HK (1) | HK1218865A1 (https=) |
| IL (1) | IL237745A0 (https=) |
| MX (1) | MX2015004564A (https=) |
| PE (1) | PE20151435A1 (https=) |
| SG (1) | SG11201501874TA (https=) |
| TW (1) | TW201420101A (https=) |
| WO (1) | WO2014058979A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| HK1198296A1 (en) | 2012-02-16 | 2015-03-27 | Teva Pharmaceutical Industries Ltd. | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EA201591507A1 (ru) * | 2013-02-15 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза лахинимодом |
| TW201609098A (zh) * | 2013-12-20 | 2016-03-16 | 泰瓦藥品工業有限公司 | 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途 |
| EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| SG10202102198RA (en) * | 2016-09-13 | 2021-04-29 | Intekrin Therapeutics Inc | Treatment of multiple sclerosis with chs-131 |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| CN113397757A (zh) * | 2021-06-07 | 2021-09-17 | 温州医科大学 | 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008527002A (ja) * | 2005-01-13 | 2008-07-24 | サートリス ファーマシューティカルズ， インコーポレイテッド | 神経変性障害および血液凝固障害を予防および処置するための新規組成物 |
| WO2008009407A2 (en) * | 2006-07-17 | 2008-01-24 | Novartis Ag | Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators |
| TW201014605A (en) * | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| RS54328B1 (sr) * | 2009-06-19 | 2016-02-29 | Teva Pharmaceutical Industries Ltd. | Tretman multiple skleroze lakvinimodom |
| PT2467372T (pt) * | 2009-08-10 | 2016-08-23 | Teva Pharma | Tratamento de distúrbios relacionados com bdnf usando laquinimod |
| WO2011086470A1 (en) * | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
| WO2012078591A1 (en) * | 2010-12-07 | 2012-06-14 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| EP2691393B1 (en) * | 2011-03-31 | 2016-09-14 | Pfizer Inc | Novel bicyclic pyridinones |
| CN106344576A (zh) * | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| TW201804997A (zh) * | 2012-05-02 | 2018-02-16 | 以色列商泰瓦藥品工業有限公司 | 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途 |
-
2013
- 2013-10-09 US US14/049,411 patent/US20140107154A1/en not_active Abandoned
- 2013-10-09 CN CN201380053184.1A patent/CN105263325A/zh active Pending
- 2013-10-09 EA EA201590726A patent/EA201590726A1/ru unknown
- 2013-10-09 MX MX2015004564A patent/MX2015004564A/es unknown
- 2013-10-09 HK HK16106893.7A patent/HK1218865A1/zh unknown
- 2013-10-09 SG SG11201501874TA patent/SG11201501874TA/en unknown
- 2013-10-09 CA CA2884272A patent/CA2884272A1/en not_active Abandoned
- 2013-10-09 BR BR112015007782A patent/BR112015007782A2/pt active Search and Examination
- 2013-10-09 KR KR1020157012465A patent/KR20150080509A/ko not_active Withdrawn
- 2013-10-09 PE PE2015000472A patent/PE20151435A1/es not_active Application Discontinuation
- 2013-10-09 WO PCT/US2013/064061 patent/WO2014058979A2/en not_active Ceased
- 2013-10-09 AU AU2013329348A patent/AU2013329348A1/en not_active Abandoned
- 2013-10-09 JP JP2015536853A patent/JP2015533163A/ja active Pending
- 2013-10-09 EP EP13895446.6A patent/EP2961406A4/en not_active Withdrawn
- 2013-10-11 AR ARP130103705A patent/AR092993A1/es unknown
- 2013-10-11 TW TW102136847A patent/TW201420101A/zh unknown
-
2015
- 2015-03-15 IL IL237745A patent/IL237745A0/en unknown
- 2015-03-23 CL CL2015000732A patent/CL2015000732A1/es unknown
-
2016
- 2016-06-17 US US15/186,163 patent/US20160296511A1/en not_active Abandoned
- 2016-11-11 CL CL2016002873A patent/CL2016002873A1/es unknown
-
2017
- 2017-06-08 AU AU2017203896A patent/AU2017203896A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150080509A (ko) | 2015-07-09 |
| EP2961406A4 (en) | 2017-01-04 |
| EA201590726A1 (ru) | 2015-10-30 |
| US20160296511A1 (en) | 2016-10-13 |
| WO2014058979A2 (en) | 2014-04-17 |
| AU2017203896A1 (en) | 2017-06-29 |
| CL2015000732A1 (es) | 2015-08-07 |
| WO2014058979A8 (en) | 2015-04-16 |
| US20140107154A1 (en) | 2014-04-17 |
| CN105263325A (zh) | 2016-01-20 |
| WO2014058979A3 (en) | 2015-08-20 |
| PE20151435A1 (es) | 2015-10-15 |
| SG11201501874TA (en) | 2015-05-28 |
| BR112015007782A2 (pt) | 2017-07-04 |
| CL2016002873A1 (es) | 2017-04-17 |
| CN105263325A8 (zh) | 2017-07-14 |
| CA2884272A1 (en) | 2014-04-17 |
| IL237745A0 (en) | 2015-05-31 |
| AU2013329348A1 (en) | 2015-05-28 |
| JP2015533163A (ja) | 2015-11-19 |
| MX2015004564A (es) | 2015-07-21 |
| EP2961406A2 (en) | 2016-01-06 |
| HK1218865A1 (zh) | 2017-03-17 |
| TW201420101A (zh) | 2014-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092993A1 (es) | Laquinimod para reducir el daño talamico en la esclerosis multiple | |
| MX2015004565A (es) | Metodo y dispositivo para conmutacion de camaras. | |
| JOP20230073A1 (ar) | بنزاميدات مستبدلة مع 3،1- ثيازول-2- يل | |
| AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| BR112015018438A2 (pt) | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento | |
| MX377157B (es) | Preparación para usarse en el tratamiento de un cáncer positivo de gd2. | |
| PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2015533163A5 (https=) | ||
| MY192813A (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
| BR112015022982A2 (pt) | inibidores macrocíclicos de rip2 quinase | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| NZ735777A (en) | Methods and compositions to inhibit symptoms associated with veisalgia | |
| MY171048A (en) | Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112014014802A2 (pt) | composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| JP2013520447A5 (https=) | ||
| BR112016016098A2 (pt) | Compostos orgânicos | |
| MX2014010989A (es) | Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos. | |
| BR112013025368A8 (pt) | Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame | |
| WO2013049280A3 (en) | Sphingosine analogs, compositions, and methods related thereto | |
| UY35748A (es) | Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |